P95 has opened its first office in the USA. Based in the Research Triangle Park in North Carolina, the largest research park in the USA, this expansion underlines P95s commitment to delivering high-quality research solutions to our clients and partners across the globe.

P95 has signed an agreement to merge OnQ Research (“OnQ”) into P95. The transaction, furthers P95’s goal of becoming the leading global, vaccine-focused CRO. P95 now has unparalleled expertise conducting research in emerging geographies on the infectious diseases which could possibly drive a future pandemic.

Leuven, Belgium, May 2nd, 2023 – P95 BV, a global provider of epidemiology and clinical research solutions with a focus on vaccines and infectious diseases, today announced a majority recapitalization by Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the life science and healthcare sectors. Ampersand’s investment will support the growth of P95’s core business and fund the expansion of its CRO services supporting the vaccine and infectious disease end-markets. As part of the transaction, P95 also announced the appointment of Benoit Bouche as Chairman of the company’s Board of Directors.

It is with great pleasure to announce that P95 has acquired Pallas Health Research and Consultancy. Pallas is an...